Herpes Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above.
Condition:   Herpes Zoster Interventions:   Biological: Low Dose Recombinant Herpes Zoster Vaccine (CHO cells);   Biological: High Dose Recombinant Herpes Zoster Vaccine (CHO cells);   Biological: Low dose adjuvant;   Biological: High dose adjuvant;   Biological: Positive control;   Biological: Placebo Sponsors:   MAXVAX Biotechnology Limited Liability Company;   Henan Center for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Condition:   Herpes Zoster Interventions:   Biological: Low Dose Recombinant Herpes Zoster Vaccine (CHO cells);   Biological: High Dose Recombinant Herpes Zoster Vaccine (CHO cells);   Biological: Low dose adjuvant;   Biological: High dose adjuvant;   Biological: Positive control;   Biological: Placebo Sponsors:   MAXVAX Biotechnology Limited Liability Company;   Henan Center for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials